Mesa Laboratories (NASDAQ:MLAB) Stock Price Crosses Above 200-Day Moving Average – Here’s Why

Mesa Laboratories, Inc. (NASDAQ:MLAB)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $93.05 and traded as high as $97.96. Mesa Laboratories shares last traded at $94.95, with a volume of 164,633 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Mesa Laboratories currently has a consensus rating of “Reduce” and an average price target of $94.00.

Mesa Laboratories Price Performance

The firm has a market cap of $523.11 million, a P/E ratio of 78.90 and a beta of 0.93. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. The stock’s 50-day simple moving average is $101.51 and its two-hundred day simple moving average is $93.15.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by ($0.25). The firm had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same quarter last year, the business posted ($1.31) EPS.

Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s payout ratio is 53.33%.

Insider Activity

In related news, CFO John Sakys sold 2,827 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $253,016.50. Following the completion of the sale, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at approximately $1,770,757.50. This trade represents a 12.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Lyndsey Elizabeth Crennen sold 442 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $39,559.00. Following the transaction, the chief accounting officer owned 2,020 shares of the company’s stock, valued at approximately $180,790. The trade was a 17.95% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 8,277 shares of company stock valued at $770,122. 4.90% of the stock is currently owned by insiders.

Institutional Trading of Mesa Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Mesa Laboratories during the 4th quarter valued at about $27,000. Kestra Advisory Services LLC bought a new stake in Mesa Laboratories during the 4th quarter valued at about $55,000. BNP Paribas Financial Markets boosted its position in Mesa Laboratories by 30.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 243 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Mesa Laboratories by 432.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after buying an additional 684 shares during the period. 90.60% of the stock is currently owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.